Ann: Investor Presentation, page-36

Great to see OCC with some strong support to hopefully reward long term investors who have long believed in the potential for this company and it's life changing products, especially the nerve product.

Management have been great and kicking goals quietly and the results in the future will speak for themselves once commercialisation hits full steam.

I am glad the company is a great liquidity position with the licencing deal earlier this year - showing management is mindful of dilution especially in a time where capital raises can be deeply discounted.

Good luck to all holders but I am hopeful we'll see multiple of our returns if the company continues to execute well.